{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:56:38Z","timestamp":1759334198088,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sociedad Argentina de Pediatria","award":["Research Grant"],"award-info":[{"award-number":["Research Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00467-025-06754-w","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T16:36:05Z","timestamp":1750955765000},"page":"3495-3503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of losartan on uric acid metabolism in children with proteinuric kidney disease: crossover randomized controlled clinical trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-8249","authenticated-orcid":false,"given":"Laura","family":"Beaudoin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-4218","authenticated-orcid":false,"given":"Luciana","family":"Meni Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-8582","authenticated-orcid":false,"given":"Sandra Mariel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-0516","authenticated-orcid":false,"given":"Ismael","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-2066","authenticated-orcid":false,"given":"Alejandro","family":"Balestracci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"6754_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00467-020-04611-6","volume":"36","author":"M Stern-Zimmer","year":"2021","unstructured":"Stern-Zimmer M, Calderon-Margalit R, Skorecki K, Vivante A (2021) Childhood risk factors for adulthood chronic kidney disease. Pediatr Nephrol 36:1387\u20131396. https:\/\/doi.org\/10.1007\/s00467-020-04611-6","journal-title":"Pediatr Nephrol"},{"key":"6754_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3904\/kjim.2020.410","volume":"35","author":"JH Park","year":"2020","unstructured":"Park JH, Jo YI, Lee JH (2020) Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med 35:1291\u20131304. https:\/\/doi.org\/10.3904\/kjim.2020.410","journal-title":"Korean J Intern Med"},{"key":"6754_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00467-008-0789-y","volume":"23","author":"E W\u00fchl","year":"2008","unstructured":"W\u00fchl E, Schaefer F (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 23:705\u2013716. https:\/\/doi.org\/10.1007\/s00467-008-0789-y","journal-title":"Pediatr Nephrol"},{"key":"6754_CR4","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","volume":"36","author":"EY Chan","year":"2021","unstructured":"Chan EY, Ma AL, Tullus K (2021) When should we start and stop ACEi\/ARB in paediatric chronic kidney disease? Pediatr Nephrol 36:1751\u20131764. https:\/\/doi.org\/10.1007\/s00467-020-04788-w","journal-title":"Pediatr Nephrol"},{"key":"6754_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/nep.12679","volume":"22","author":"YP Hsieh","year":"2017","unstructured":"Hsieh YP, Chang CC, Yang Y, Wen YK, Chiu PF, Lin CC (2017) The role of uric acid in chronic kidney disease patients. Nephrology (Carlton) 22:441\u2013448. https:\/\/doi.org\/10.1111\/nep.12679","journal-title":"Nephrology (Carlton)"},{"key":"6754_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00467-018-3979-2","volume":"34","author":"DJ Weaver Jr","year":"2019","unstructured":"Weaver DJ Jr (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34:801\u2013809. https:\/\/doi.org\/10.1007\/s00467-018-3979-2","journal-title":"Pediatr Nephrol"},{"key":"6754_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811\u20131821. https:\/\/doi.org\/10.1056\/NEJMra0800885","journal-title":"N Engl J Med"},{"key":"6754_CR8","doi-asserted-by":"publisher","first-page":"102271","DOI":"10.1016\/j.redox.2022.102271","volume":"51","author":"WT Crawley","year":"2022","unstructured":"Crawley WT, Jungels CG, Stenmark KR, Fini MA (2022) U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol 51:102271. https:\/\/doi.org\/10.1016\/j.redox.2022.102271","journal-title":"Redox Biol"},{"key":"6754_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000326848","volume":"33","author":"H Sonoda","year":"2011","unstructured":"Sonoda H, Takase H, Dohi Y, Kimura G (2011) Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33:352\u2013357. https:\/\/doi.org\/10.1159\/000326848","journal-title":"Am J Nephrol"},{"key":"6754_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1053\/j.ajkd.2015.06.015","volume":"66","author":"KE Rodenbach","year":"2015","unstructured":"Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ (2015) Hyperuricemia and progression of CKD in children and adolescents: the chronic kidney disease in children (CKiD) cohort study. Am J Kidney Dis 66:984\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.015","journal-title":"Am J Kidney Dis"},{"key":"6754_CR11","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00467-020-04713-1","volume":"35","author":"R Hogg","year":"2020","unstructured":"Hogg R (2020) \u201cDisproportionate\u201d hyperuricemia in children with hemolytic uremic syndrome (HUS): should we regard this as a \u201cmedical emergency\u201d? Pediatr Nephrol 35:2205\u20132210. https:\/\/doi.org\/10.1007\/s00467-020-04713-1","journal-title":"Pediatr Nephrol"},{"key":"6754_CR12","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00467-018-4046-8","volume":"34","author":"BR Stotter","year":"2019","unstructured":"Stotter BR, Ferguson MA (2019) Should ACE inhibitors and ARBs be used in combination in children? Pediatr Nephrol 34:1521\u20131532. https:\/\/doi.org\/10.1007\/s00467-018-4046-8","journal-title":"Pediatr Nephrol"},{"key":"6754_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00467-012-2374-7","volume":"28","author":"MG Caletti","year":"2013","unstructured":"Caletti MG, Balestracci A, Missoni M, Vezzani C (2013) Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol 28:745\u2013750. https:\/\/doi.org\/10.1007\/s00467-012-2374-7","journal-title":"Pediatr Nephrol"},{"key":"6754_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/0897190019866315","volume":"33","author":"EM Sutton Burke","year":"2020","unstructured":"Sutton Burke EM, Kelly TC, Shoales LA, Nagel AK (2020) Angiotensin receptor blockers effect on serum uric acid-A class effect? J Pharm Pract 33:874\u2013881. https:\/\/doi.org\/10.1177\/0897190019866315","journal-title":"J Pharm Pract"},{"key":"6754_CR15","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1007\/s00467-021-05045-4","volume":"36","author":"CE Bryant","year":"2021","unstructured":"Bryant CE, Rajai A, Webb NJA, Hogg RJ (2021) Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. Pediatr Nephrol 36:3211\u20133219. https:\/\/doi.org\/10.1007\/s00467-021-05045-4","journal-title":"Pediatr Nephrol"},{"key":"6754_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 8:18. https:\/\/doi.org\/10.1186\/1741-7015-8-18","journal-title":"BMC Med"},{"key":"6754_CR17","unstructured":"Dose Equivalence: ACEi and ARB. London New Drugs Group APC\/DTC Briefing Document (2008) http:\/\/askdis.blogspot.com\/2017\/06\/dose-equivalence-acei-and-arb.html. Accessed 21 Mar 2022"},{"key":"6754_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/ajh.2008.245","volume":"21","author":"T Hamada","year":"2008","unstructured":"Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A, Shigamasa C, Yamamoto Y, Ninomiya H, Hisatome I (2008) Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21:1157\u20131162. https:\/\/doi.org\/10.1038\/ajh.2008.245","journal-title":"Am J Hypertens"},{"key":"6754_CR19","unstructured":"Ministerio de Salud de Argentina (2020) Interpretaci\u00f3n y uso de las nuevas tablas de referencia de presi\u00f3n arterial para ni\u00f1os, ni\u00f1as y adolescentes Programa Nacional de Salud Escolar (PROSANE). https:\/\/www.argentina.gob.ar\/sites\/default\/files\/bancos\/2021-04\/interpretacion-uso-nuevas-tablas-referencia-de-presion-arterial-prosane-2020.pdf. Accessed 15 Apr 2022"},{"key":"6754_CR20","doi-asserted-by":"publisher","unstructured":"Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS,\u00a0National Kidney Foundation's Kidney Disease Outcomes Quality Initiative\u00a0(2003) National Kidney Foundation\u2019s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416\u20131421. https:\/\/doi.org\/10.1542\/peds.111.6.1416","DOI":"10.1542\/peds.111.6.1416"},{"key":"6754_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6754_CR22","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"6754_CR23","doi-asserted-by":"publisher","first-page":"3480718","DOI":"10.1155\/2019\/3480718","volume":"2019","author":"M Kubota","year":"2019","unstructured":"Kubota M (2019) Hyperuricemia in children and adolescents: present knowledge and future directions. J Nutr Metab 2019:3480718. https:\/\/doi.org\/10.1155\/2019\/3480718","journal-title":"J Nutr Metab"},{"key":"6754_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00467-013-2549-x","volume":"29","author":"SA Fathallah-Shaykh","year":"2014","unstructured":"Fathallah-Shaykh SA, Cramer MT (2014) Uric acid and the kidney. Pediatr Nephrol 29:999\u20131008. https:\/\/doi.org\/10.1007\/s00467-013-2549-x","journal-title":"Pediatr Nephrol"},{"key":"6754_CR25","first-page":"S205","volume":"117","author":"Sociedad Argentina de Cardiolog\u00eda and Sociedad Argentina de Pediatr\u00eda","year":"2019","unstructured":"Sociedad Argentina de Cardiolog\u00eda and Sociedad Argentina de Pediatr\u00eda (2019) Consensus on cardiovascular prevention in childhood and adolescence Brief version. Recommendations. Arch Argent Pediatr 117:S205\u2013S242","journal-title":"Arch Argent Pediatr"},{"key":"6754_CR26","unstructured":"World Health Organization. Child growth Standards https:\/\/www.who.int\/toolkits\/child-growth-standards\/standards\/body-mass-index-for-age-bmi-for-age. Accessed 20 Sep 2023"},{"key":"6754_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","volume":"20","author":"A Dang","year":"2006","unstructured":"Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B (2006) Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 20:45\u201350. https:\/\/doi.org\/10.1038\/sj.jhh.1001941","journal-title":"J Hum Hypertens"},{"key":"6754_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","volume":"19","author":"G W\u00fcrzner","year":"2001","unstructured":"W\u00fcrzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M (2001) Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855\u20131860. https:\/\/doi.org\/10.1097\/00004872-200110000-00021","journal-title":"J Hypertens"},{"key":"6754_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00467-022-05620-3","volume":"38","author":"GJ Schwartz","year":"2023","unstructured":"Schwartz GJ, Roem JL, Hooper SR, Furth SL, Weaver DJ Jr, Warady BA, Schneider MF (2023) Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents. Pediatr Nephrol 38:489\u2013497. https:\/\/doi.org\/10.1007\/s00467-022-05620-3","journal-title":"Pediatr Nephrol"},{"key":"6754_CR30","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1038\/s41598-019-43241-3","volume":"9","author":"TR Oh","year":"2019","unstructured":"Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, Sung SA, Kim YS, Oh KH, Ahn C, Kim SW (2019) Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep 9:6681. https:\/\/doi.org\/10.1038\/s41598-019-43241-3","journal-title":"Sci Rep"},{"key":"6754_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00467-022-05753-5","volume":"38","author":"A Balestracci","year":"2023","unstructured":"Balestracci A, MeniBattaglia L, Toledo I, Beaudoin L, Martin SM, Grisol\u00eda NA, Hogg RJ (2023) Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome. Pediatr Nephrol 38:1547\u20131557. https:\/\/doi.org\/10.1007\/s00467-022-05753-5","journal-title":"Pediatr Nephrol"},{"key":"6754_CR32","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00467-020-04644-x","volume":"35","author":"MH Cho","year":"2020","unstructured":"Cho MH, Ahn YH, Lim SH, Kim JH, Ha IS, Cheong HI, Kang HG (2020) Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome. Pediatr Nephrol 35:2183\u20132189. https:\/\/doi.org\/10.1007\/s00467-020-04644-x","journal-title":"Pediatr Nephrol"},{"key":"6754_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41440-023-01252-8","volume":"46","author":"SI Tsukamoto","year":"2023","unstructured":"Tsukamoto SI, Wakui H, Tamura K (2023) Effects of Uric Acid-Lowering Therapy on the Kidney (HTR-2023-0096.R2). Hypertens Res 46:1447\u20131449. https:\/\/doi.org\/10.1038\/s41440-023-01252-8","journal-title":"Hypertens Res"},{"key":"6754_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58:2\u20137. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.171488","journal-title":"Hypertension"},{"key":"6754_CR35","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa035700","journal-title":"N Engl J Med"},{"key":"6754_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.acuro.2020.09.006","volume":"45","author":"M UbetagoyenaArrieta","year":"2021","unstructured":"UbetagoyenaArrieta M, AresesTrapote R, MendiaUbetagoyena J, P\u00e9rez Revuelta MS, LetonaLuqui M (2021) Renal lithiasis in pediatric patients: correlation of methods that depend on 24-hour collections with simpler methods that do not require timed urine. Actas Urol Esp (Engl Ed) 45:146\u2013153. https:\/\/doi.org\/10.1016\/j.acuro.2020.09.006","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"6754_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2223\/JPED.826","volume":"78","author":"MG Penido","year":"2002","unstructured":"Penido MG, Diniz JS, Guimar\u00e3es MM, Cardoso RB, Souto MF, Penido MG (2002) Excre\u00e7\u00e3o urin\u00e1ria de c\u00e1lcio, \u00e1cido \u00farico e citrato em crian\u00e7as e adolescentes sadios [Urinary excretion of calcium, uric acid and citrate in healthy children and adolescents]. J Pediatr (Rio J) 78:153\u2013160","journal-title":"J Pediatr (Rio J)"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06754-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:09:00Z","timestamp":1759234140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06754-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6754"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06754-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of our institution (IRB 7122).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.This trial has been registered at  (identifier NCT05402397).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}